Monday December 10, 2018

Jharkhand Governor Draupadi Murmu pledges to donate Eyes at Run of Vision programme by Kashyap Memorial Eye Hospital

Till now 426 people have donated eyes to KMEH out of which 366 have been transplanted successfully

1
//
Kashyap Memorial Eye Hospital. Image source: Facebook
Republish
Reprint

Ranchi, Septemeber 03, 2016: Jharkhand Governor Draupadi Murmu announced on Saturday that she will donate her eyes at the Run of Vision programme organised by Kashyap Memorial Eye Hospital (KMEH), Ranchi.

Talking to IANS, Dr Bharti Kashyap, Medical Director of the KMEH said: “We are obliged that governor madam announced to donate her eyes so that a blind person can see the world. We express our deep gratitude to the governor.”

Follow NewsGram on Twitter

“We have been organising Run For Vision programme for the last 11 years to create awareness among people of the state to donate their eyes. According to reports, in our country every year 25,000 to 30,000 people suffer from blindness due to cornea related problems. Cornea cannot be purchased and can only be transplanted from one human being to another,” she added.

Till now 426 people have donated eyes to KMEH out of which 366 have been transplanted successfully.

Follow NewsGram on Facebook

Leaders who have announced to donate eyes to KMEH include Congress leader Jairam Ramesh, former Chief Minister and BJP leader Arjun Munda among others.

Speaking on the occasion, the governor said: “Of the 37 million people suffering from blindness in the world 10 million are from India. There is a need to create awareness by organising camps.” (IANS)

Click here for reuse options!
Copyright 2016 NewsGram

  • Arya Sharan

    Great move by the leaders, it will increase awareness about eye donation and will consequently help the blind population.

Next Story

New Drug Offers Treatment For Diabetes-Related Blindness

The researchers now plan to conduct a full-scale clinical trial, Gamble said

0
new policy will see the launch of 12 programmes relevant to private schools across the emirate
New drug offers hope for diabetes-related blindness.

In a major breakthrough, Australian scientists have developed a new drug that offers treatment for people suffering from diabetic retinopathy — the main cause of blindness from diabetes.

The debilitating disease occurs when tiny blood vessels in the retina, responsible for detecting light, leak fluid or haemorrhage.

While treatment options include laser surgery or eye injections of anti-vascular endothelial growth factor (VEGF), they are not always effective or can result in side effects, highlighting the need for alternative therapeutic approaches.

The team from the Centenary Institute in Sydney developed a novel drug CD5-2, which in mouse models was found to mend the damaged blood retinal barrier and reduce vascular leakage.

“We believe CD5-2 could potentially be used as a stand-alone therapy to treat those patients who fail to respond to the anti-VEGF treatment. It may also work in conjunction with existing anti-VEGF treatments to extend the effectiveness of the treatment,” said lead author Ka Ka Ting from the Institute.

“With limited treatment options currently available, it is critical we develop alternative strategies for the treatment of this outcome of diabetes,” Ting added.

Diabetes
Representational image. Pixabay

The key process involved in diabetic retinopathy pathology is the breakdown of the blood-retinal barrier (BRB), which is normally impermeable. Its integrity relies on how well capillary endothelial cells are bound together by tight junctions. If the junctions are loose or damaged, the blood vessels can leak.

In the study, reported in the journal Diabetologia, CD5-2 was found to have therapeutic potential for individuals with vascular-leak-associated retinal diseases based on its ease of delivery and its ability to reverse vascular dysfunction as well as inflammatory aspects in animal models of retinopathy.

Previous studies have shown that CD5-2 can have positive effects on the growth of blood vessels.

Also Read- Facebook Invests $1 mn To Boost Computer Science Education

“This drug has shown great promise for the treatment of several major health problems, in the eye and in the brain,” said Professor Jenny Gamble, head of Centenary’s Vascular Biology Programme.

The researchers now plan to conduct a full-scale clinical trial, Gamble said. (IANS)